» Articles » PMID: 26827698

Proton Beams in Cancer Treatments: Clinical Outcomes and Dosimetric Comparisons with Photon Therapy

Overview
Publisher Elsevier
Specialty Oncology
Date 2016 Feb 2
PMID 26827698
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To review current evidence of the role of proton therapy (PT) in other tumors than skull base, sinusal/parasinusal, spinal and pediatric tumors; to determine medico-economic aspects raised by PT.

Material And Methods: A systematic review on Medline was performed with the following keywords: proton therapy, proton beam, protontherapy, cancer; publications with comparison between PT and photon-therapy were also selected.

Results: In silico studies have shown superiority (better dose delivery to the target and/or to organs at risk) of PT toward photon-therapy in most of thoracic and abdominal malignant tumors. Potential benefits of PT could be: reduction of toxicities (including radiation-induced cancer), increase of tumor control through a dose-escalation approach, hypofractionation. Cost of treatment is always cited as an issue which actually can be managed by a precise patient selection making PT a cost-effective procedure. Comparison plan with photon therapy may be useful to determine the dosimetric and clinical advantages of PT (Normal Tissue Complications Probability).

Conclusion: PT may be associated with a great advantage compared to the best photon-therapies in various types of cancers. Accumulation of clinical data is on-going and will challenge the in silico data analysis. Some indications are associated with strong superiority of PT and may be discussed as a new standard within prospective observational studies.

Citing Articles

Exploring the Potential of Gold Nanoparticles in Proton Therapy: Mechanisms, Advances, and Clinical Horizons.

Carbone G, Mariano S, Gabriele A, Cennamo S, Primiceri V, Aziz M Pharmaceutics. 2025; 17(2).

PMID: 40006543 PMC: 11859620. DOI: 10.3390/pharmaceutics17020176.


Initial feasibility cohort of temporally modulated pulsed proton re-irradiation (TMPPR) for recurrent high-grade intracranial malignancies.

La Rosa A, Fellows Z, Wroe A, Coutinho L, Pons E, McAllister N Sci Rep. 2024; 14(1):26685.

PMID: 39496803 PMC: 11535062. DOI: 10.1038/s41598-024-78370-x.


Balancing Innovation and Patient Care in Breast Cancer: Integrating Hypofractionated Proton Therapy With Breast Reconstruction Outcomes.

Fatima H, Abbas P, Alshehri S Cureus. 2024; 16(4):e58056.

PMID: 38738134 PMC: 11088419. DOI: 10.7759/cureus.58056.


Radiation-induced skin and heart toxicity in patients with breast cancer treated with adjuvant proton radiotherapy: a comparison with photon radiotherapy.

Hsieh C, Yu C, Chu C, Chen W, Chen M Am J Cancer Res. 2023; 13(10):4783-4793.

PMID: 37970351 PMC: 10636671.


An Overview of Head and Neck Tumor Reirradiation: What Has Been Achieved So Far?.

Gordon K, Smyk D, Gulidov I, Golubev K, Fatkhudinov T Cancers (Basel). 2023; 15(17).

PMID: 37686685 PMC: 10486419. DOI: 10.3390/cancers15174409.